Swiss Venture Capital Report 2025 (SECA (Swiss Private Equity and Corporate Finance Association))

Summary

• The biotech sector led investment recovery with CHF 739.2 million invested, an increase of more than 50 % over the previous year.p.6
• Across all financing rounds, the median investment size rose by 40.7 % to CHF 3.0 million.p.6
• Capital invested in Canton Zurich start-ups dropped by 27.1 %, while Canton Vaud grew by 13.3 % and Canton Geneva surged by 81.3 %.p.6

Key insights

1. Alentis Therapeutics secured the year's largest single financing round with a CHF 160.0 million series D investment.p.9
2. Cleantech start-ups demonstrated strength by capturing seven of the 20 largest financing rounds of the year.p.6
3. Later stage financing transactions showed resilience by securing CHF 1,504 million compared with CHF 1,513 million in 2023.p.20
4. Investor sentiment rebounded significantly, with 76 % expecting higher Swiss investment volumes in the next 12 months.p.6
5. Cadence acquired Greek-Swiss simulation technology company BETA CAE Systems International for approximately USD 1.24 billion.p.38
6. Johnson & Johnson acquired Numab Therapeutics subsidiary Yellow Jersey Therapeutics for USD 1.25 billion in cash.p.56